Binds Specifically-identified Amino Acid Sequence Patents (Class 530/387.9)
-
Publication number: 20150050308Abstract: A new coronavirus is disclosed herein with a tropism that includes humans. Means and methods are provided for diagnosing subjects (previously) infected with the virus. Also provided are among others vaccines, medicaments, nucleic acids and specific binding members.Type: ApplicationFiled: August 13, 2014Publication date: February 19, 2015Inventor: Cornelia Maria van der Hoek
-
Publication number: 20150051378Abstract: This invention features methods and compositions useful for treating and diagnosing diseases of the nervous system, retina, skin, muscle, joint, and cartilage using a Dragon family protein. Protein and nucleic acid sequences of human, murine, zebrafish, and C. elegans Dragon family members are also disclosed.Type: ApplicationFiled: June 17, 2014Publication date: February 19, 2015Inventors: Clifford J. Woolf, Tarek A. Samad
-
Publication number: 20150051377Abstract: This invention features methods and compositions useful for treating and diagnosing diseases of the nervous system, retina, skin, muscle, joint, and cartilage using a Dragon family protein. Protein and nucleic acid sequences of human, murine, zebrafish, and C. elegans Dragon family members are also disclosed.Type: ApplicationFiled: June 17, 2014Publication date: February 19, 2015Inventors: Clifford J. Woolf, Tarek A. Samad
-
Publication number: 20150051379Abstract: Methods of detecting synovial sarcoma using differentially expressed genes are disclosed. Also disclosed are methods of identifying agents for treating synovial sarcoma. Further, a method for treating or preventing a disease that is associated with Frizzled homologue 10 (FZD10) in a subject is provided.Type: ApplicationFiled: July 30, 2014Publication date: February 19, 2015Inventors: Yusuke NAKAMURA, Toyomasa KATAGIRI, Chikako FUKUKAWA, Motoki KUHARA
-
Patent number: 8956869Abstract: The present invention provides a novel peptide that can be effectively used to produce or grow tissue-specific stem cells or tissue-specific progenitor cells in vitro. The peptide of the invention is a peptide having an amino acid sequence consisting of the amino acid residues set forth in SEQ ID NO:1, or an analog thereof. A feature of the peptide of the invention is having at least one of the following effects: (1) an effect of inhibiting differentiation of hematopoietic stem cells or hematopoietic progenitor cells into myeloid cells, (2) an effect of promoting amplification of mesenchymal stem cells, and (3) an effect of inducing hematopoietic stem cells from pluripotent stem cells.Type: GrantFiled: September 29, 2010Date of Patent: February 17, 2015Assignee: Kyushu University, National University CorporationInventor: Daisuke Sugiyama
-
Publication number: 20150044704Abstract: The disclosure relates to antibodies to the preferentially expressed antigen in melanoma (PRAME), and the synovial sarcoma X breakpoint 2 (SSX-2) antigens, methods of use, and diagnostic kits thereof. In exemplary embodiments, the disclosure relates to monoclonal antibodies to specific epitopes of the PRAME and SSX-2 antigens and methods of using such antibodies.Type: ApplicationFiled: August 5, 2014Publication date: February 12, 2015Inventors: Nathalie KERTESZ, Sutao ZHU, Chih-Sheng CHIANG
-
Publication number: 20150044703Abstract: Some embodiments of the present invention relate to methods and compositions for detecting the presence of cancer. In particular, methods and compositions for detecting endometrial cancer or ovarian cancer are provided.Type: ApplicationFiled: March 12, 2013Publication date: February 12, 2015Applicant: University of South AlabamaInventors: Michael A. Finan, Rodney P. Rocconi, Lewis K. Pannel
-
Publication number: 20150047060Abstract: A non-human transgenic animal having a polynucleotide encoding a PTN polypeptide, which polynucleotide is operably linked to a promoter, wherein said transgenic animal has greater than wild-type expression of the PTN polypeptide in at least one brain region, as well as related vectors, methods of producing transgenic animals, in vitro and in vivo screening methods for potential therapeutic agents, and methods for treating and diagnosing neuropsychiatric illnesses, particularly anxiety and depression, are disclosed.Type: ApplicationFiled: March 14, 2013Publication date: February 12, 2015Applicant: BRAINCO BIOPHARMA, S.L.Inventors: David Arteta, Marcelo Ferrer, Laureano Simon, Antonio Martinez, Maria Uribarri
-
Publication number: 20150044221Abstract: This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof as a therapeutic and/or preventive agent for cancer. Specifically, this invention provides an antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence, and a pharmaceutical composition for treatment and/or prevention of cancer, comprising the antibody or fragment thereof as an active ingredient.Type: ApplicationFiled: February 21, 2013Publication date: February 12, 2015Inventors: Shinichi Kobayashi, Fumiyoshi Okano, Takanori Saito
-
Publication number: 20150045541Abstract: Monoclonal antibodies, or fragments thereof, are used for isolating and/or identifying at least one cell population. The cell population can include any of the following types of cells: haematopoietic stem cells, neuronal stem cells, neuronal progenitor cells, mesenchymal stem cells and mesenchymal progenitor cells. The antibodies, or fragments thereof, bind to an antigen which is the same as that bound by an antibody which is produced by the hybridoma cell lines CUB1, CUB2, CUB3 and CUB4, which were deposited in the DSMZ under the numbers DSM ACC2569, DSM ACC2566 and DSM ACC2565, on Aug. 14, 2002, and DSM ACC2551, on Jul. 7, 2002.Type: ApplicationFiled: September 19, 2014Publication date: February 12, 2015Inventors: HANS-JOERG BUEHRING, REINER LAMMERS, SELIM KUCI, TIM CONZE
-
Publication number: 20150044700Abstract: An anti-GAP43 antibody which is capable of distinguishing a non-phosphorylated threonine residue at position 89 (T89) from a phosphorylated threonine residue at position 89 (pT89) of mouse GAP43 set forth in SEQ ID NO: 13, and which is capable of specifically detecting a growth cone; an anti-GAP43 antibody which is capable of distinguishing a non-phosphorylated serine residue at position 96 (S96) from a phosphorylated serine residue at position 96 (pS96) of mouse GAP43, and which is capable of specifically detecting a growth cone; an anti-GAP43 antibody which is capable of distinguishing a non-phosphorylated threonine residue at position 172 (T172) from a phosphorylated threonine residue at position 172 (pT172) of mouse GAP43, and which is capable of specifically detecting a growth cone; and an immunological analysis method using these anti-GAP43 antibodies.Type: ApplicationFiled: October 19, 2012Publication date: February 12, 2015Inventors: Kosei Takeuchi, Michihiro Igarashi, Motohiro Nozumi, Asami Kawasaki
-
Patent number: 8952135Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. agalactiae, and methods for isolating such antigens and specific uses thereof.Type: GrantFiled: May 6, 2013Date of Patent: February 10, 2015Assignee: Valneva Austria GmbHInventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Markus Horky, Sabine Kallenda, Sonja Prustomersky
-
Patent number: 8951519Abstract: The present invention is directed to pharmaceutical agents and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.Type: GrantFiled: February 21, 2013Date of Patent: February 10, 2015Assignee: New York UniversityInventors: Thomas M. Wisniewski, Fernando Goni
-
Patent number: 8951963Abstract: The invention provides a peptide triazole conjugate and derivatives thereof, and methods of its use. The invention also provides an antibody to the peptide triazole conjugate. The invention further provides a method of identifying an HIV-1 entry inhibitor candidate.Type: GrantFiled: March 27, 2013Date of Patent: February 10, 2015Assignee: Drexel UniversityInventors: Irwin M. Chaiken, Umashankara Muddegowda, Karyn McFadden
-
Publication number: 20150038683Abstract: The present invention features methods and compositions for the generation and use of conformation-specific antibodies or fragments thereof.Type: ApplicationFiled: July 7, 2014Publication date: February 5, 2015Inventors: Kun Ping LU, Xiao Zhen Zhou
-
Publication number: 20150037341Abstract: The present invention relates to a method of treating or preventing transthyretin amyloidosis, pharmaceutical composition for use in said treatment or prevention, as well as to a diagnostic method and a kit.Type: ApplicationFiled: February 21, 2012Publication date: February 5, 2015Applicant: Plysackaridforskning i Uppsala ABInventors: Ulf Lindahl, Jin-ping Li, Fredrik Noborn
-
Publication number: 20150037343Abstract: An Ang2 specific antibody, a method of inhibiting angiogenesis or a method of treating a disease related to the activation and/or overproduction of Ang2 using the antibody, and a composition for diagnosing a disease related to the activation and/or overproduction of Ang2 including the antibody.Type: ApplicationFiled: July 30, 2014Publication date: February 5, 2015Inventors: Seok Kyun KIM, Sang Yeul Han, Kwang Hoon Lee, Kyung Eun Kim, Chung Ho Kim, Yong In Kim, Hyung-Chan Kim, Yoon Sook Lee, Hyo Seon Lee
-
Publication number: 20150037251Abstract: The invention relates inhibiting nucleic acids directed at mammalian homologues of the Drosophila fwe gene (Flower) and to antibodies against the respective proteins, and their use in diagnosing, preventing and treating cancer.Type: ApplicationFiled: February 18, 2013Publication date: February 5, 2015Applicants: UNIVERSITAT BERN, CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICASInventors: Christa Rhiner, Evgeniya Pertova, Jesus M. Lopez-Gay, Eduardo Moreno
-
Publication number: 20150037345Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.Type: ApplicationFiled: October 13, 2014Publication date: February 5, 2015Inventors: Ronald Vogels, Theodorus Hendrikus Jacobus Kwaks
-
Publication number: 20150037339Abstract: The present invention provides antibodies that bind to Activin A and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Activin A with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders characterized by decreased muscle mass or strength, such as sarcopenia, cachexia, muscle injury, muscle wasting/atrophy, cancer, fibrosis, and weight loss. The antibodies of the invention are also useful in combination with GDF8 binding proteins for the treatment of diseases and disorders characterized by decreased muscle mass or strength. The antibodies of the invention are also useful for the prevention, treatment, or amelioration of disorders and diseases caused by, promoted by, exacerbated by, and/or aggravated by Activin A, such as renal fibrosis.Type: ApplicationFiled: July 30, 2014Publication date: February 5, 2015Inventors: Jesper Gromada, Esther Latres, Andrew Murphy, George Yancopoulis, Lori Morton
-
Publication number: 20150037324Abstract: Described herein are antibodies against GPR49 and uses of such antibodies. Various aspects relate to monoclonal, humanized, or fully human antibodies against GPR49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies, and methods of treating cancer with such antibodies.Type: ApplicationFiled: October 31, 2012Publication date: February 5, 2015Inventors: Christopher L. Reyes, Peter Chu, Xiangyang Tan, Christilyn Graff, Weixing Yang
-
Publication number: 20150037905Abstract: Provided herein methods for determining whether a subject, particularly a human subject, is at risk of developing, having, or experiencing a complication of cardiovascular disease, and methods of treating subjects who are identified by the current methods of being at risk for cardiovascular disease. In one embodiment, the method comprises determining levels of one or more oxidized apolipoprotein A-I related biomolecules in a bodily sample from the subject. Also, provided are kits and reagents for use in the present methods. Also provided are methods for monitoring the status of cardiovascular disease in a subject or the effects of therapeutic agents on subjects with cardiovascular disease. Such method comprising determining levels of one or more oxidized apolipoprotein A-I related molecules in bodily samples taken from the subject over time or before and after therapy.Type: ApplicationFiled: May 12, 2014Publication date: February 5, 2015Applicant: THE CLEVELAND CLINIC FOUNDATIONInventors: Stanley L. Hazen, Michael Kinter, Marc S. Penn, Jonathan Smith, Lemin Zheng
-
Publication number: 20150037284Abstract: The present invention relates to a novel Listeria bacteriophage designated ProCC P825. In particular, the present invention relates to the endolysin PlyP825 encoded by the novel phage ProCC P825 and uses of the novel endolysin PlyP825 for controlling Listeria contamination and infection.Type: ApplicationFiled: May 29, 2012Publication date: February 5, 2015Applicant: DSM IP ASSETS B.V.Inventors: Holger Grallert, Julia Lorenz, Anna Scherzinger
-
Publication number: 20150037364Abstract: Baboon Adenovirus (BaAdV)-2/4 and BaAdV-3 are disclosed herein. BaAdV-2/4 and BaAdV-3 polynucleotide, polypeptides and antibodies that specifically bind BaAdV-2/4 and/or BaAdV-3 are disclosed. Methods are disclosed for detecting BaAdV-2/4 and BaAdV-3. Methods are also disclosed for treating, preventing, and inducing an immune response to BaAdV-2/4 and/or BaAdV-3. Kits are also provided.Type: ApplicationFiled: January 15, 2014Publication date: February 5, 2015Inventors: Charles Chiu, Jean Patterson, Mary Michelle Leland, Kenneth Dee Carey, Dean Ehrdman
-
Publication number: 20150037344Abstract: The present invention relates to agents which modulate the effect of a RAMP (Receptor Activity Modifying Protein) protein on a Calcitonin Receptor Like Receptor (CRLR). Also included in the present invention are methods and uses of such agents and assays for identifying such agents. The agents of the present disclosure may be used in the treatment of, for example, cancer, obesity and other disorders.Type: ApplicationFiled: October 9, 2014Publication date: February 5, 2015Inventors: Timothy Michael SKERRY, Gareth Owain RICHARDS
-
Patent number: 8945570Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.Type: GrantFiled: October 26, 2012Date of Patent: February 3, 2015Assignee: Agensys, Inc.Inventors: Aya Jakobovits, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
-
Patent number: 8945566Abstract: The invention provides a method for increasing the bioactivity (e.g. the biosafety and efficacy) of a therapeutic IgE antibody of the invention in the treatment of a patient. Methods of the invention include: i) administering to the patient a therapeutic IgE antibody in combination with at least one bioactivity-enhancing agent, ii) strategic treatment regimens and protocols for the dosing and administration of a therapeutic IgE antibody of the invention, and iii) the use of a therapeutic IgE antibody having a variable region comprising at least one antigen binding region specific for binding an epitope of an antigen wherein the epitope is not highly repetitive or is non-repetitive.Type: GrantFiled: April 26, 2012Date of Patent: February 3, 2015Assignee: Quest PharmaTech, Inc.Inventors: Birgit C. Schultes, Christopher F. Nicodemus
-
Patent number: 8945548Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.Type: GrantFiled: October 3, 2013Date of Patent: February 3, 2015Assignee: Novartis AGInventors: Jose M. Carballido Herrera, Stefan Hartle, Christoph Heusser, Ingo Klagge, Andrea Polzer, Christoph Schwaerzler, Gabriela Wochnik-Veltrup
-
Publication number: 20150030607Abstract: Disclosed herein are neutralizing antibodies with cross-neutralizing activity and cross-protective effects against divergent stains of influenza virus, which are specific for an epitope having at least 90% homology to amino acids +72-115 of the HA1 domain of H5N1 influenza virus hemagglutinin.Type: ApplicationFiled: October 9, 2014Publication date: January 29, 2015Inventors: Shibo Jiang, Lanying DU, Yusen Zhou
-
Publication number: 20150031624Abstract: The invention provides a chimeric antigen receptor (CAR) (a) an antigen binding domain of HN1 or SS, a transmembrane domain, and an intracellular T cell signaling domain, or (b) an antigen binding domain of SS1, a transmembrane domain, an intracellular T cell signaling domain, and a granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor 2 leader. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: ApplicationFiled: March 5, 2013Publication date: January 29, 2015Inventors: Steven A. Feldman, Steven A. Rosenberg, Ira H. Pastan
-
Publication number: 20150030601Abstract: The invention provides isolated nucleic acids molecules, designated UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid molecules, which encode novel E1 enzyme variant proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a UBA3, UAE, or UBA6, or other E1 enzyme variant gene has been introduced or disrupted. The invention still further provides isolated UBA3, UAE, or UBA6, or other E1 enzyme variant proteins, fusion proteins, antigenic peptides and anti-UBA3, UAE, or UBA6, or other E1 enzyme variant antibodies. The invention provides methods to identify agents that inhibit UBA3, UAE, or UBA6, or other E1 enzyme variant expression or activity. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: October 5, 2012Publication date: January 29, 2015Applicant: Millennium Pharmaceuticals, Inc.Inventors: Benjamin Stone Amidon, James E. Brownell, James M. Gavin, Erik M. Koenig, Michael D. Sintchak, Peter G. Smith
-
Publication number: 20150030606Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.Type: ApplicationFiled: October 7, 2014Publication date: January 29, 2015Inventors: Ravindra Kumar, Asya Grinberg, Monique Davies, Diana Martik, Janja Cosic, Rachel Kent, David Buckler
-
Publication number: 20150030603Abstract: An anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes with a Tie2 receptor and Ang2, and related methods and compositions.Type: ApplicationFiled: July 29, 2014Publication date: January 29, 2015Inventors: Kyung Eun KIM, Seung Ja Oh, Hyo Seon Lee, Sang Yeul Han
-
Publication number: 20150030600Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.Type: ApplicationFiled: August 31, 2011Publication date: January 29, 2015Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: James D. Marks, Yongfeng Fan, Jianlong Lou, Maria Consuelo Garcia Rodriguez, Shude Yan, Isin Nergiz Geren, Wenwu Zhai, Subhendu Chakraborti
-
Publication number: 20150030602Abstract: A novel monoclonal antibody and like antigen-binding molecules against transmembrane protein with EGF-like and two follistatin-like domains 2 (TMEFE2) are provided with unique immunological and biological properties useful in the therapy of affective disorders such as depression and bipolar disorders as well as anxiety disorders. In addition, pharmaceutical compositions and kits comprising such antibody and derivatives thereof are described.Type: ApplicationFiled: January 2, 2013Publication date: January 29, 2015Applicant: PHENOQUEST AGInventors: Ingeborg Sillaber, Marcelo Paez-Pereda
-
Publication number: 20150031748Abstract: There is provided a method of identifying candidate agents capable of modulating interaction between a first polypeptide and a second polypeptide, wherein the first polypeptide is ZO-2/TJP2 or a functional variant thereof and the second polypeptide is a Snail zinc finger transcription factor family member or a functional variant thereof.Type: ApplicationFiled: February 28, 2013Publication date: January 29, 2015Applicant: Agency for Science, Technology and ResearchInventors: Walter Hunziker, Choon Peng Goh
-
Publication number: 20150030586Abstract: Compositions and methods for the therapy and diagnosis of cancer are disclosed. For example, illustrative compositions comprise one or more cancer-associated antibodies, polypeptides, polynucleotides, antigen presenting cells, and the like. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly cancer.Type: ApplicationFiled: June 19, 2012Publication date: January 29, 2015Inventors: Sarah Ellen Warren, Carl Weissman
-
Publication number: 20150033417Abstract: The present invention provides DNA molecules that constitute fragments of the genome of a plant, and polypeptides encoded thereby. The DNA molecules are useful for specifying a gene product in cells, either as a promoter or as a protein coding sequence or as an UTR or as a 3? termination sequence, and are also useful in controlling the behavior of a gene in the chromosome, in controlling the expression of a gene or as tools for genetic mapping, recognizing or isolating identical or related DNA fragments, or identification of a particular individual organism, or for clustering of a group of organisms with a common trait. One of ordinary skill in the art, having this data, can obtain cloned DNA fragments, synthetic DNA fragments or polypeptides constituting desired sequences by recombinant methodology known in the art or described herein.Type: ApplicationFiled: December 3, 2004Publication date: January 29, 2015Inventors: Nickolai Alexandrov, Nestor Apuya, Vyacheslav Brover, Jean-Baptiste Dumas, Yiwen Fang, Ken Feldmann, Diane Jofuku, Edward A. Kiegle, Bill Kimmerly, Shing Kwok, Peter Mascia, Jack Okamuro, Roger Pennell, Richard Schneeberger, Tatiana Tatarinova, Wayne Volkmuth
-
Publication number: 20150030605Abstract: The invention encompasses polypeptides, polynucleotides, and antibodies, for Artemin and related ligands, including Persephin (PSPN). The invention also encompasses expression vectors and host cells for producing these polypeptides, polynucleotides, or antibodies. The invention further encompasses diagnostics and therapeutics, especially for cancer, and particularly breast cancer, colon cancer, prostate cancer, endometrial cancer, lung cancer, stomach cancer, liver cancer, and others, comprising one or more of the disclosed polypeptides, polynucleotides, antibodies, expression vectors, host cells, or compositions thereof. Particularly encompasses are inhibitors of Artemin and/or related ligands, and uses for these inhibitors.Type: ApplicationFiled: September 19, 2014Publication date: January 29, 2015Inventors: Liu Dongxu, Peter Edward Lobie
-
Patent number: 8940272Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: October 11, 2011Date of Patent: January 27, 2015Assignees: University of Zurich, Biogen Idec International Neuroscience GmbHInventors: Roger Nitsch, Feng Chen, Jan Grimm, Jean-Luc Baeriswyl, Christoph Hock
-
Patent number: 8940874Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle or bone, or disorders of insulin metabolism.Type: GrantFiled: November 30, 2012Date of Patent: January 27, 2015Assignees: Wyeth LLC, MedImmune LimitedInventors: Geertruida M. Veldman, Monique V. Davies, Kening Song, Neil M. Wolfman, Kristie Grove Bridges, Anne Field, Caroline Russell, Viia Valge-Archer
-
Patent number: 8940872Abstract: The present invention provides an antibody that specifically binds to an abnormal TDP-43 protein aggregate, an agent comprising the antibody for detecting a TDP-43 proteinopathy lesion, and a method for detecting or diagnosing a TDP-43 proteinopathy lesion by using the antibody.Type: GrantFiled: July 7, 2008Date of Patent: January 27, 2015Assignee: Tokyo Metropolitan Institute of Medical ScienceInventors: Masato Hasegawa, Tetsuaki Arai, Takashi Nonaka, Fuyuki Kametani, Haruhiko Akiyama
-
Publication number: 20150023974Abstract: The present invention relates to the identification of a TLR2 binding epitope wherein binding of a binding member to the epitope serves to inhibit TLR2 activation and/or signalling. Polypeptide fragments of TLR2 and three-dimensional structures comprising one or more amino acid residues His318, Pro320, Gln321 or Arg321, Tyr323, Lys347, Phe349, Leu371, Glu375, Tyr376 and His398 of TLR2 which define the identified epitope are provided for use in generating binding members. Also provided are binding members which bind to the identified epitope and methods of using same for the treatment and/or prevention of conditions associated with TLR2 activation and/or signalling.Type: ApplicationFiled: March 29, 2013Publication date: January 22, 2015Inventors: Nils Kuklik, Wolf-Dieter Schubert
-
Publication number: 20150023976Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.Type: ApplicationFiled: October 9, 2014Publication date: January 22, 2015Inventors: Steven G. NADLER, James K. TAMURA, Laura PRICE, Robert P. REHFUSS, Suzanne J. SUCHARD, Anish SURI, James William BRYSON, Aaron YAMNIUK, Steven GRANT, Olga IGNATOVICH, Philip DREW
-
Publication number: 20150023969Abstract: The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.Type: ApplicationFiled: January 31, 2012Publication date: January 22, 2015Applicant: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling, Lisa L. Herron Olson
-
Publication number: 20150023871Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.Type: ApplicationFiled: September 29, 2014Publication date: January 22, 2015Applicant: GENENTECH, INC.Inventors: Paul Polakis, Jyoti Asundi, Ron Firestein, Robert F. Kelley, Krista McCutcheon
-
Publication number: 20150025225Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits enzyme activity of EL and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: ApplicationFiled: October 11, 2012Publication date: January 22, 2015Inventors: Shoichi Naito, Junji Onoda, Tasuku Tsukamoto, Katsutoshi Yamada, Shoji Yamane, Yoshito Numata, Kazuhiko Maekawa, Tatsuya Takahashi, Yasuhiko Sato
-
Publication number: 20150023951Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.Type: ApplicationFiled: February 3, 2014Publication date: January 22, 2015Applicant: Genentech, Inc.Inventors: Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-yee Chen
-
Publication number: 20150023957Abstract: Isolated SAA peptides, fusion proteins and compositions comprising such are provided as are domain-specific SAA antibodies. Methods of treating sepsis and endotoxemia are also provided.Type: ApplicationFiled: July 9, 2014Publication date: January 22, 2015Applicant: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCHInventors: Haichao Wang, Andrew E. Sama, Wei Li, Kevin J. Tracey
-
Publication number: 20150023999Abstract: The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.Type: ApplicationFiled: November 29, 2012Publication date: January 22, 2015Inventors: Simon Urwyler, Markus Haake, Michael Rodolf